Endothelial progenitor cells and rheumatic disease modifying therapy

Area of Science:

• Cardiovascular Research
• Rheumatology
• Vascular Biology

Background:

• Rheumatic diseases are linked to accelerated atherosclerosis and higher cardiovascular disease (CVD) risk.
• Vascular inflammation, endothelial dysfunction, and traditional risk factors contribute to CVD in rheumatic conditions.
• Circulating endothelial progenitor cells (EPCs) are crucial for endothelial repair but are often impaired in rheumatic diseases.

Purpose of the Study:

• To review current knowledge on improving EPC number and function in rheumatic diseases.
• To explore the potential of pharmaceutical and lifestyle interventions for EPC restoration.
• To assess the impact of improved EPCs on preventing cardiovascular complications in rheumatic patients.

Main Methods:

• Literature review of studies on EPCs in rheumatic diseases.
• Analysis of pharmaceutical interventions targeting EPCs.
• Evaluation of lifestyle interventions affecting EPCs.
• Synthesis of evidence on EPC dysfunction and CVD risk in rheumatic conditions.

Main Results:

• Abnormalities in EPC number and function are consistently reported in rheumatic diseases.
• Growing interest exists in EPCs as a therapeutic target for CVD.
• Early studies suggest pharmacological strategies may improve EPC dysfunction.

Conclusions:

• Restoring EPC function is a potential therapeutic avenue for reducing CVD in rheumatic diseases.
• The effectiveness of interventions in preventing cardiovascular complications requires further investigation.
• Further research is needed to establish optimal strategies for enhancing EPCs in rheumatic conditions.